- Home
- COHR vs MRNA Comparison
COHR vs MRNA Comparison
Compare COHR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COHR | MRNA |
|---|---|---|
| Founded | 1971 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9B | 11.5B |
| IPO Year | 1987 | 2018 |
Fundamental Metrics
Financial Performance| Metric | COHR | MRNA |
|---|---|---|
| Price | $191.11 | $34.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 13 |
| Target Price | ★ $146.85 | $33.25 |
| AVG Volume (30 Days) | 5.0M | ★ 10.5M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $6,043,358,000.00 | $2,232,000,000.00 |
| Revenue This Year | $17.38 | N/A |
| Revenue Next Year | $13.50 | $0.77 |
| P/E Ratio | $244.18 | ★ N/A |
| Revenue Growth | ★ 20.80 | N/A |
| 52 Week Low | $45.58 | $22.28 |
| 52 Week High | $200.19 | $48.92 |
Technical Indicators
Market Signals| Indicator | COHR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 80.43 |
| Support Level | $170.12 | $28.66 |
| Resistance Level | $186.67 | $30.44 |
| Average True Range (ATR) | 12.02 | 1.58 |
| MACD | -0.89 | 0.73 |
| Stochastic Oscillator | 78.37 | 91.60 |
Price Performance
Historical ComparisonAbout COHR Coherent Corp.
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.